Literature DB >> 29216931

VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.

Sabrina Ceeraz1,2, Susan K Eszterhas1,3, Petra A Sergent1,2, David A Armstrong4,5, Alix Ashare4,5, Thomas Broughton1,2, Li Wang6, Dov Pechenick7, Christopher M Burns8, Randolph J Noelle1,2,7, Matthew P Vincenti3,5, Roy A Fava9,10.   

Abstract

BACKGROUND: In addition to activated T cells, the immune checkpoint inhibitor "V domain-containing Ig suppressor of T-cell activation" (VISTA) is expressed by myeloid cell types, including macrophages and neutrophils. The importance of VISTA expression by myeloid cells to antibody-induced arthritis and its potential for relevance in human disease was evaluated.
METHODS: VISTA was immunolocalized in normal and arthritic human synovial tissue sections and synovial tissue lysates were subjected to western blot analysis. The collagen antibody-induced arthritis model (CAIA) was performed with DBA/1 J mice treated with antibodies against VISTA and with VISTA-deficient mice (V-KO). Total mRNA from arthritic joints, spleens, and cultured macrophages was analyzed with NanoString arrays. Cytokines secreted by splenic inflammatory macrophages were determined. In-vitro chemotaxis and signal transduction assays were performed with cultured macrophages.
RESULTS: VISTA protein was localized to synovial membrane cells, neutrophils, and scattered cells in lymphocyte-rich foci and was detected by western blot analysis in normal synovium and synovium from rheumatoid arthritis patients. Deficiency of VISTA or treatment of mice with anti-VISTA monoclonal antibodies attenuated CAIA. Joint damage and MMP-3 expression were significantly reduced in V-KO mice. Surface expression of C5a receptor was reduced on monocytes, neutrophils, and cultured macrophages from V-KO. Upon Fc receptor engagement in vitro, gene expression by V-KO macrophages was altered profoundly compared to WT, including a significant induction of IL-1 receptor antagonist (IL1rn).
CONCLUSIONS: VISTA expression supports immune-complex inflammation in CAIA and VISTA is expressed in human synovium. VISTA supports optimal responses to C5a and modulates macrophage responses to immune complexes.

Entities:  

Keywords:  Antigen–antibody complex; Arthritis; Autoimmunity; Complement; Macrophages; Receptors

Mesh:

Substances:

Year:  2017        PMID: 29216931      PMCID: PMC5721690          DOI: 10.1186/s13075-017-1474-y

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  37 in total

Review 1.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  M Feldmann; R N Maini
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

2.  A VISTA on PD-1H.

Authors:  Yang Liu
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

Review 3.  Role of C5a in inflammatory responses.

Authors:  Ren-Feng Guo; Peter A Ward
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.

Authors:  Li Wang; Isabelle Le Mercier; Juan Putra; Wenna Chen; Jun Liu; Austin D Schenk; Elizabeth C Nowak; Arief A Suriawinata; Jiannan Li; Randolph J Noelle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

5.  Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.

Authors:  Dallas B Flies; Tomoe Higuchi; Lieping Chen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 6.  Anakinra for rheumatoid arthritis: a systematic review.

Authors:  Marty Mertens; Jasvinder A Singh
Journal:  J Rheumatol       Date:  2009-05-15       Impact factor: 4.666

7.  Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies.

Authors:  R Holmdahl; L Jansson; A Larsson; R Jonsson
Journal:  Scand J Immunol       Date:  1990-02       Impact factor: 3.487

8.  Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals.

Authors:  Preeti Bharaj; Harendra Singh Chahar; Ogechika K Alozie; Lizette Rodarte; Anju Bansal; Paul A Goepfert; Alok Dwivedi; N Manjunath; Premlata Shankar
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

9.  VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

Authors:  J Louise Lines; Lorenzo F Sempere; Thomas Broughton; Li Wang; Randolph Noelle
Journal:  Cancer Immunol Res       Date:  2014-06       Impact factor: 11.151

10.  Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis.

Authors:  Hélène Asnagli; Delphine Martire; Nathalie Belmonte; Julie Quentin; Hervé Bastian; Mathilde Boucard-Jourdin; Papa Babacar Fall; Anne-Laure Mausset-Bonnefont; Amélie Mantello-Moreau; Sandrine Rouquier; Irène Marchetti; Christian Jorgensen; Arnaud Foussat; Pascale Louis-Plence
Journal:  Arthritis Res Ther       Date:  2014-05-22       Impact factor: 5.156

View more
  17 in total

Review 1.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 2.  VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Authors:  Mohamed A ElTanbouly; Walburga Croteau; Randolph J Noelle; J Louise Lines
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 3.  Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.

Authors:  Stinne Ravn Greisen; Bent Deleuran
Journal:  Curr Rheumatol Rep       Date:  2021-03-02       Impact factor: 4.592

Review 4.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Authors:  Wenwen Xu; TạMinh Hiếu; Subramaniam Malarkannan; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 5.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

6.  Effects of Human Adipose Tissue-Derived and Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in a Dextran Sulfate Sodium-Induced Mouse Model.

Authors:  Shunzo Ikarashi; Atsunori Tsuchiya; Yuzo Kawata; Yuichi Kojima; Takayuki Watanabe; Suguru Takeuchi; Katsuhide Igarashi; Maky Ideta-Otsuka; Katsuyuki Oki; Masaaki Takamura; Shuji Terai
Journal:  Biores Open Access       Date:  2019-11-11

7.  Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness.

Authors:  Thomas W K Broughton; Mohamed A ElTanbouly; Evelien Schaafsma; Jie Deng; Aurélien Sarde; Walburga Croteau; Jiannan Li; Elizabeth C Nowak; Rodwell Mabaera; Nicole C Smits; Anna Kuta; Randolph J Noelle; J Louise Lines
Journal:  Front Immunol       Date:  2019-11-19       Impact factor: 8.786

Review 8.  The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.

Authors:  Negar Hosseinkhani; Afshin Derakhshani; Mahdi Abdoli Shadbad; Antonella Argentiero; Vito Racanelli; Tohid Kazemi; Ahad Mokhtarzadeh; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.

Authors:  Rebeca Hid Cadena; Rosanne D Reitsema; Minke G Huitema; Yannick van Sleen; Kornelis S M van der Geest; Peter Heeringa; Annemieke M H Boots; Wayel H Abdulahad; Elisabeth Brouwer
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

Review 10.  Resistance to Checkpoint Inhibition in Cancer Immunotherapy.

Authors:  Luisa Barrueto; Francheska Caminero; Lindsay Cash; Courtney Makris; Purushottam Lamichhane; Rahul R Deshmukh
Journal:  Transl Oncol       Date:  2020-02-27       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.